2018 Winners
The 2018 winners are:
Best ADC Platform Technology
Sutro Biopharma (nnAA Conjugation) -WINNER
LegoChem Bio (Scaffold Based Approach) – Runner Up
Best New Drug Developer
Bicycle Therapeutics- WINNER
Sutro Biopharma-Runner Up
Most Promising Clinical Candidate
Polatuzumab Vedotin- WINNER
Sacituzumab Govitecan (IMMU-132)-Runner Up
Best Contract Manufacturing (CMO) Provider
BSP Pharmaceuticals- WINNER
Novasep-Runner Up
Best Contract Research (CRO) Provider
Charles River- WINNER
Abzena-Runner Up
Best Publication in 2017
Rovalpituzumab tesirine, a DLL3-targeted antibody-drugconjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR; SCRX16-001 investigators. Lancet Oncol. 2017 Jan;18(1):42-51.- WINNER
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H 3rd, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P. J Clin Oncol. 2017 Jan 10;35(2):141-148.-Runner Up
Individual Input to the Field 2017
Philipp Mueller, Boehringer Ingelheim -WINNER
Long Standing Contribution to the Field
Dr Ravi Chari, ImmunoGen – WINNER